Euroopa Liit - tšehhi - EMA (European Medicines Agency)

takeda pharma a/s - alogliptin benzoát, metformin hydrochloridu - diabetes mellitus, typ 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - vipdomet is indicated in the treatment of adult patients aged 18 years and older with type-2 diabetes mellitus:as an adjunct to diet and exercise to improve glycaemic control in adult patients, inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of alogliptin and metformin;in combination with pioglitazone (i. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and pioglitazone;in combination with insulin (i. trojkombinační léčbě) jako doplněk k dietním opatřením a cvičení s cílem zlepšit úpravu glykémie u pacientů s inzulín na stabilní dávce a metforminu samotného nezajistí dostatečnou kontrolu glykémie.

Euroopa Liit - tšehhi - EMA (European Medicines Agency)

astellas pharma europe b.v. - enzalutamid - prostatetické novotvary - endokrinní terapie - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.

Euroopa Liit - tšehhi - EMA (European Medicines Agency)

takeda pharma a/s - brigatinib - karcinom, plicní jiná než malobuněčná - antineoplastická činidla - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.

Euroopa Liit - tšehhi - EMA (European Medicines Agency)

amryt pharmaceuticals dac - dry extract from birch bark (der 5-10 : 1), extraction solvent n-heptane 95% (w/w) - epidermolysis bullosa dystrophica; epidermolysis bullosa, junctional - přípravky pro léčbu ran a vředů - treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (eb) in patients 6 months and older.

Euroopa Liit - tšehhi - EMA (European Medicines Agency)

roche registration gmbh - pertuzumab, trastuzumab - neoplasmy prsů - antineoplastická činidla - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy in:the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrencethe adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrencemetastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.

Euroopa Liit - tšehhi - EMA (European Medicines Agency)

pinax pharma gmbh - joflupan (123i) - radionuclide imaging; dementia; movement disorders - diagnostické radiofarmaka - tento léčivý přípravek je určen pouze pro diagnostické účely. celsunax is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:in adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic parkinson’s disease, multiple system atrophy and progressive supranuclear palsy.  celsunax is unable to discriminate between parkinson's disease, multiple system atrophy and progressive supranuclear palsy. u dospělých pacientů, pomoci odlišit pravděpodobné demence s lewyho tělísky od alzheimerovy choroby.  celsunax is unable to discriminate between dementia with lewy bodies and parkinson’s disease dementia.

Euroopa Liit - tšehhi - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - spesolimab - psoriáza - imunosupresiva - spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (gpp) as monotherapy.

Euroopa Liit - tšehhi - EMA (European Medicines Agency)

amryt pharmaceuticals dac - octreotide acetate - acromegalie - hypofýzy a hypotalamické hormony a analogy - mycapssa is indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.

Tšehhi - tšehhi - SUKL (Státní ústav pro kontrolu léčiv)

rotop radiopharmacy gmbh, dresden array - 14794 joflupan-(123i) - injekční roztok - 74mbq/ml - joflupan-(123i)

Tšehhi - tšehhi - SUKL (Státní ústav pro kontrolu léčiv)

teva pharmaceuticals cr, s.r.o., praha array - 14074 anastrozol - potahovaná tableta - 1mg - anastrozol